New Hardware and Software Developments for Improving Prostate Metabolic MR Imaging

项目总结/摘要 拟议的F31 NRSA博士前奖学金，以促进健康相关研究项目的多样性，目的是 开发新的MR探测器硬件和采集与分析方法，以实现 前列腺癌的临床管理。这对所有前列腺癌患者都有意义，但也特别重要。 代表性不足的少数民族。非洲裔美国男性前列腺癌发病率居世界首位 死亡率是白人的两倍多。此外，非洲裔美国人有两次 非西班牙裔白人患晚期前列腺癌的风险。这意味着 重要的是，在这个代表性不足的地区准确识别和分期侵袭性，晚期前列腺癌， 人口我们小组先前的研究集中在改善原发性、器官- 局限性前列腺癌和检测对骨和肝（远端）转移治疗的反应。PI，一个 非裔美国研究生，设计了这个多样性奖学金的拟议研究培训 一个专注于开发新的13 C/1H RF检测器硬件和方法的项目，用于增加HP [1- 13 C]丙酮酸盐 & 1H mpMRI的灵敏度和覆盖范围，以检测前列腺内的侵袭性癌症和局部扩散到 前列腺床及邻近淋巴结。这对新诊断的患者很重要， 对于非裔美国人患者，他们更经常表现为具有囊外的晚期疾病， 扩散到前列腺和附近的淋巴结。 正如他所附的biosketch和通过他出色的初步研究显示，候选人是一个高度 积极主动，成功的受训者谁符合资格标准，作为一个非洲裔美国研究生，并将 从他的研究，教育和努力促进多样性方面受益匪浅， 生物医学研究该项目由PI申请人设计（有赞助商的输入和指导），以适应他的 我的职业目标是成为一名教授，领导先进的MRI技术开发，以改善临床护理 特别是前列腺癌患者，以及其他致命疾病的患者。该奖项还将 使PI候选人能够促进加州大学伯克利分校和加州大学旧金山分校联合生物工程项目的多样性 并最终在全国范围内扩大少数民族科学家的数量和投入 尤其是在生物工程领域。他一直高度积极地促进多样性目前作为一个UC生物 研究生和黑人研究生工程和科学学生（BGESS）的成员。之多样 奖学金职业发展计划旨在扩大科学知识和独立研究 候选人的能力。目标是：1）提高MR硬件的知识和研究技能， 采集方法; 2）学习研究设计和实施; 3）统计和临床研究考虑因素; 和4）进行一流的研究，旨在最终改善前列腺癌成像的新 诊断为晚期疾病的患者。

Project Summary/Abstract The proposed F31 NRSA Predoctoral Fellowship to Promote Diversity in Health-Related Research project aims to develop new MR detector hardware and acquisition & analysis methods to enable a major improvement in the clinical management of prostate cancer. This is of relevance to all prostate cancer patients, but also especially for under-represented minorities. African-American men have the world's highest incidence of prostate cancer and a more than two-fold higher mortality rate compared with whites. Also, African-American men have twice the risk of non-Hispanic whites for presenting with advanced-stage prostate cancer. This means that it is important to identify and stage aggressive, advanced prostate cancer accurately in this under-represented population. Prior studies by our group have been focused on improved MR molecular imaging of primary, organ- confined prostate-cancer and detecting response to therapy in bone and liver (distant) metastases. The PI, an African-American graduate student, has designed the proposed research training in this diversity fellowship project to focus on developing novel 13C/1H RF detector hardware and methods for increased HP [1-13C]pyruvate & 1H mpMRI sensitivity and coverage to detect aggressive cancers within the prostate and local spread to the prostatic bed & adjacent lymph-nodes. This is important for newly diagnosed patients and of particular relevance for African-American patients who more often present with advanced stage disease that has extra-capsular spread beyond the prostate and to nearby lymph nodes. As shown in his attached biosketch and through his outstanding initial research, the candidate is a highly motivated, successful trainee who meets the eligibility criteria as an African-American graduate student and will benefit greatly from this fellowship in terms of his research, education, and efforts to promote diversity in biomedical research. This project was designed by the PI applicant (with sponsor input & guidance) to fit his career goal of becoming a professor leading advanced MRI technology development to improve the clinical care of prostate cancer patients specifically, and patients with other deadly diseases in general. This award will also enable the PI candidate to promote diversity within the joint Bioengineering program at UC Berkeley and UCSF and ultimately science nationally to expand the number and input of under-represented minority scientists especially in the field of Bioengineering. He has been highly active in promoting diversity currently as a UC BioE graduate student and a member of Black Graduate Engineering and Science Students (BGESS). The diversity fellowship career development plan is designed to expand the scientific knowledge and independent research capabilities of the candidate. The goals are to: 1) Improve knowledge and research skills in MR hardware and acquisition methods; 2) Learn research study design and conduct; 3) Statistical and clinical study considerations; and 4) the conduct of first-rate research designed to ultimately improve prostate cancer imaging of newly diagnosed patients presenting with advanced disease.